A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.
Status:
Completed
Trial end date:
2019-05-20
Target enrollment:
Participant gender:
Summary
This study is a prospective, open-label, single-arm intervention study in
African-American/Black subjects with heart failure and reduced ejection fraction (HFrEF).
There will be a 7-day screening period, a 57-day open-label treatment period, and a safety
follow-up at day 87 or 30 days after the last administration of the investigational product.